| 标题 |
[求助补充材料]
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study |
| 备注 |
仅需完整Supplementary Material,尤其Table S1各臂Grade 3–5治疗期间不良事件原表;正文已有,无需正文。用于个人科研阅读。
💡 该求助存在备注,如果存在信息冲突,请以备注为准
|
| 网址 | |
| DOI | |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人或该文件上传人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)